Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
Background Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication in patients with chronic or resolved HBV infection undergoing anticancer therapy. There is a risk of HBV reactivation after infusion of chimeric antigen receptor (CAR) T cells for patients with refractory/...
Main Authors: | Jian Zhou, Lu Han, Keshu Zhou, Baijun Fang, Linlin Li, Quanli Gao, Hu Zhou, Yongping Song, Qingsong Yin, Xinghu Zhu, Lingdi Zhao, Xudong Wei, Bengling Xu, Jishuai Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000927.full |
Similar Items
-
Single VHH-directed BCMA CAR-NK cells for multiple myeloma
by: Quan Ren, et al.
Published: (2023-11-01) -
sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
by: Katja Seipel, et al.
Published: (2022-03-01) -
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
by: Xiangmin Wang, et al.
Published: (2021-12-01) -
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
by: Robert Berahovich, et al.
Published: (2018-09-01) -
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
by: Vita Golubovskaya, et al.
Published: (2021-10-01)